Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Miss Scarlet,
You are a very funny lady. Thanks for the support.
Warmest regards,
Blue
Easymedicine,
My English isn’t good? What, you didn’t like my alliteration (DNAP Doom) and my reference of American history? I heralded you as the DNAP Doomsayer. I would think that someone as magnanimous as you would find that a compliment. Truly your motives are purely altruistic since you hardly own any DNAP, right? You state my post is nonsense and you attack when all I asked for was when because you stated definitely. I knew that you would weasel on an exact date so I alluded to a year (1 year, 2 years, 3 years?). At least you are staying true to your MO. .... You did it with Doug S. and now you are doing it with me. I guess you’re still not willing to even give a year.
Big Blue
Easymedicine:
.0001 is definitely coming. ...really?
Definitely? You have a definite affinity to post the emphatic. So when is it coming? You have been the proverbial Paul Revere of DNAP Doom for several months now with your cry of .0001 is coming, .0001 is coming. And you know what I don't know if it is or isn't but somehow you know, right? So, when? You have bashed the DNAP PRs for not having a timeline yet when you are asked by T-Vegas, when is .0001 coming? You come back with no time frame and a DEFINATELY? You have crossed the line to a classic basher. Sure, there are many issues with this company and cash flow is the biggest issue of all….we all know that here. However, there are some promising aspects to the company too and as stated before many Investors know the risk. So I ask you as T-Vegas has, when is .0001 coming? …..1 year, 2 years, 3 years?
Can you stand behind your emphatic words?
Thanks for the kind words Miss S. and to you too cosmic.
Big Blue
Yesterday
There were a few of us yesterday that tried to calm the waters and discredit those who were screaming that we would lose our shares. I may have been harsher than some….I get that way sometimes when people mislead others. I hate the injustice and manipulation of it. I would like to thank chrisbaskett, uncxman, stakddek, retired investor, matrix, cosmiclifeform for standing with me and working the truth out a day ahead of the press release. Sincerely…thank you.
To the bashers, I hope that you all realize the weight of the PR of 4/5. This is the first PR of its kind for DNAP in that they will be creating / enhancing a drug and to the point will have exclusive rights to a drug that already has several patents. This appears to essentially give DNAP 8 patents from 0 because it is exclusive. There are those that state, “well, there is no time table”. This is true as far as we know; however, we are not privy to everything and PT-401 is already discovered. Plus, DNAP’s enhancements will come from tech that they already have. How much (blind) faith do you need to think that Harvard would agree to an exclusive deal that will not produce? Some perhaps…but not much. The PR is not a guarantee for revenue…this also is true, but it is the best news that DNAP has ever (IMHO) come out with. Look at the facts and not conjecture:
We have an exclusive deal with one of the most reputable medical organizations in the world.
We have essentially picked up the rights to several patents.
We are working on a drug that already has a billion dollar market in a lesser form.
Lastly, we are working on a drug that the FDA as already approved the core form and application for.
I wish the honest well and the misguided peace, enlightenment, and a clean pure soul before you pass.
Big, I love this stuff, Blue
_____________________
"Our EPO technology has significant promise as a more powerful and commercially successful application of Erythropoietin," stated BIDMC's Dr. Arthur J. Sytkowski, who holds patents related to the new "Super"-EPO. "We are pleased that DNAPrint has made a commitment to work with BIDMC in expanding the potential for this drug."
The human gene that produces EPO was cloned in 1985, and, in 1989, scientists at Amgen introduced to market a recombinant form under the trade name EPOGEN®, a drug that many credit for the rise of Amgen in the 1990s as one of the world's most successful biotechnology companies ever.
Patients undergoing certain therapies or with certain conditions are often rendered anemic, meaning their red blood cell count drops dramatically. Without adequate amounts of erythropoietin in the blood, red blood cells are not regenerated efficiently, and there are too few red blood cells to deliver oxygen sufficiently throughout the body. Erythropoietin has been approved by the U.S. Food and Drug Administration as a treatment for anemia associated with renal failure, cancer chemotherapy, zidovudine-treated HIV-infected patients and to reduce blood transfusion in surgery patients. Anemia leaves patients tired, often impairing their ability to work or perform even routine tasks and over the last decade, EPO has proven to improve quality of life and overall fitness of those patients.
In 1995, Dr. Sytkowski, Director for the Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology at Beth Israel Deaconess, was awarded the first in a string of eight patents covering methods of producing and using recombinant protein multimers with increased biological activity. In these patents, which are subject of the exclusive DNAPrint license announced today, Dr. Sytkowski described a new dimer (double) form of EPO -- "Super"-EPO, that elicited a heartier, more predictable hematocrit (red blood cell count) response, constituting a significant improvement over existing EPO technology.
You Know Nothing
•I called you out on your approach of the message.
•I asked you for nothing, go reread my post.
•The OTCBB trades are easier but people can trade and invest just fine on the pink.
•“Nobody wanted to believe what was about to happen” You know nothing. You do not know if they are going private, you do not know if they are going pink, you know nothing.
•As stated before, the form is for S.D.E. Holdings 1, Inc. that has 0 share holders! You know nothing! I own lots of shares of DNAP so is it a shell that DNAP wants to just clean up….? I don’t know but that is the likely scenario.
•Get off this board and stop misleading the masses.
Due your own DD but don't post crap that is misleading! Is GE a pink now too?! Please. Look, if you want people to listen to you have some respect for yourself and don't mislead people. You want to accept reality (as you stated)? The reality is that you posted a link with no follow-up and no comment. That action by you was diliberate so people would go to the site called Pink Sheets and see DNAP.
How about some more reality...IF DNAP goes pink that means lower costs ....take a look at NFFCA and look when the company went pink.
What is you point in giving us this link?!
You are getting to the point of trying to mislead people. Here's a link for you: http://www.pinksheets.com/quote/quote.jsp?symbol=ge
To the point just because a stock shows on this site does not mean they are pink.
Leading Forensic Human Identification E-Symposium April 14, 2005
Tuesday March 1, 3:00 am ET
International Web Conference Launches With Free Registration for Law Enforcement, Lawyers and Academics
LONDON, March 1 /PRNewswire/ -- The Forensic Institute, in conjunction with e-symposium, are presenting, as part of their international web conference series, the 1st International Human Identification E-Symposium (HumID 2005). It will be held online on the 14 April 2005. In addition to the live event, delegates will have access to the presentation archive throughout the year -- all from the comfort of their own office.
The program covers cutting edge topics and reads like the "who is who" of human identification:
DNA Speakers: Dr. John Buckleton (ESR), Dr. Peter Gill (Forensic Science Service), Dr. Bruce Budowle (FBI), Dr. John M. Butler (NIST), Prof. David Kaye (ASU)
Fingerprints Speakers: Peter Komarinski (IAI), Stephen Meagher (FBI), Dr. Ian Evett (Forensic Science Service), Prof. Christophe Champod (UNIL), Simon A. Cole (Cornell Univ.), Prof. Michael Saks (ASU), Colin Patton (PITO)
Biometrics Speakers: Dr. Fred Preston, PITO, Peter Komarinski (IAI)
Mass Disaster/Terrorism Victim Identification Speaker: Prof. Sue Black (Dundee Univ.)
Round Table Debates: The Bayesian Approach to Evidence Evaluation (Prof. Allan Jamieson, Prof. Bernard Robertson, Dr. Ian Evett), Fingerprints -- Science or Not (Colin Patton, Prof. Christophe Champod, Simon A. Cole, Stephen Meagher)
Keynote: Prof. David Faigman (UC Hastings College of the Law)
Sponsorship Speakers: Tom Gluodenis (Agilent), Dr. Tony Frudakis (DNAPrint), Dr. Terry Melton (Mitotyping Technologies), Dr. Ripan Malhi (Trace Genetics).
If this isn't enough to convince you, the event is reviewed by Dr. Bob Bramley, Prof. Jim Fraser, Prof. Kenneth G. Furton, Ron Singer, Prof. Pierre Margot, Dr. Erkki Sippola, Prof. Allan Jamieson and Prof. Michael Saks.
Registration for industry professionals is free of charge. "The unique value of our international web conferences is that they cut down the budget and time barriers usually associated with offline conferences," says Val-Pierre Genton, Managing Director of e-symposium and the E-Symposium's Co-Chair. The free-of-charge strategy is expected to generate attendance levels in excess of 1,000 delegates and create unprecedented knowledge-sharing from experts to delegates. It seems that the E-Symposium covers every angle -- not only can delegates attend high quality presentations from the comfort of their own office, but they can also interact with their international colleagues via cutting edge web-based instant messaging technology. Delegates can even create private, secured 'rooms' to have closed meetings. With training and travel budgets tight or non-existent, this certainly is deliverance for the legal, law enforcement and academic communities.
For more information and to register, visit us at http://www.humid.e-symposium.com/speaker-program.php .
Its not but I guess I have to S-plain it to ya.
Your post is 50+ minutes later. I was writing for the moment and people were selling. As you know the bid / ask changes throughout the day. Look at a chart for today and you will see that the price tanked as compared to where it was from 2 to 2:30.
Big, good-times...good-times, Blue
You're right on target. 500% or more gain....?
There are too many people selling into the good news right now and the stock is falling. Traders that are happy with 40 to 50% gains will likely be sorry within the next few years. JMHO.
Hey Dorsey,
Sorry to jump in on your request to Frog....but I do not think that the subject is open for opinion.
Since the FDA came out with its new guidence (IMO) its been clear that DNAP would have to apply for a 510K for Stat. and Ov. Check out #2 below. Number 2 appears to speak directly to DNAP's genomic-based diagnostic tests. Although, the 10 was just released it is my hope that they wrote their statement about further FDA guidence prior to the new guidelines coming out.
If you're interested in looking into it further you can check CFR 312.23. The info below is from: http://www.fda.gov/cder/genomics/decisionTree.htm
Big, I love this stuff, Blue
Pharmacogenomic data must be submitted to the IND under CFR 312.23 if ANY of the following apply:
1. The test results are used for making decisions pertaining to a specific clinical trial, or in a animal trial used to support safety (e.g., the results will affect dose selection, entry criteria into a clinical trial safety monitoring, or subject stratification).
2. A sponsor is using the test results to support scientific arguments pertaining to, for example, the pharmacologic mechanism of action, the selection of drug dosing, or the safety and effectiveness of a drug.
3. The test results constitute a known, or probable, valid biomarker for physiologic, pathophysiologic, pharmacologic, toxicologic, or clinical states or outcomes in humans, or is a known valid biomarker for a safety outcome in animal studies. If the information on the biomarker (example, human CYP2D6 status) is not being used for purposes 1 or 2 above, the information can be submitted to the IND as an abbreviated report.
I plan on checking the Patents every few weeks as long as I am invested in DNAP. I like most here trade some, put away some, and invest in a few regardless of price. Obviously, DNAP is one that I am invested in. I can afford to play here, I enjoy this board & hope that my contributions are helpful for the long-investors, and I'm reservedly optimistic for the company knowing full well what could happen on both ends of the spectrum.
Big Blue
A Reply To Chrisbaskett:
All you need to do is go to the US Patent Office web site. I've posted the URL below:
http://www.uspto.gov/
When you get to the site (you should have the patent #s in hand) look to the left and you will see under the menu of Patents a section called Status & IFW. Just click on Status & IFW and put in the Patent Number you want to check out.
Since having any patent would give a more tangible value to DNAPrint. I have reviewed several of these, as I have stated in my posts. I find it promising that there's been activity over the last 2 months. With, Methods for the Identification of Genetic Features for Complex Genetics Classifiers Patent app, there was forward progress just on 3/15/2005. Also, with Compositions and Methods for Inferring a Response to Statin Patent app there's been activity last month. Since Statins are widely prescribed with Lipitor being the world's #1 prescrided drug I have tracked the Compositions and Methods for Inferring a Response to Statin Patent most of all.
Hope this helps you,
Big Blue
More Patent movement in the last week.
Some Notes
I have just reviewed many of the pending patents listed on the DNAP site at the USPTO site. There has been activity on a couple of pending patents as recently as February 2005. As I recall, there have been many on this board that thought or still believe that the patents are approved; unfortunately, this is not the case (yet) as I have reported before. If the makers of Propolene can get a patent I have faith that DNAP can too (I hate that Propolene commercial!).
About a month ago, I as many of you notified DNAP regarding their website and other matters. At a minimum, they have responded with some updates on the web site.
Big Blue
GO-DNAP....
has stated news would be coming out in the past and the result turned out to be nothing. I expect that to happen again, nothing. If GO-DNAP is right and DNAP News comes out at 4:00 I would be shocked. I like most on this board am hopeful for DNAP's long-term profitability and success; therefore, a good PR would be welcome and exciting for most. However, when hope, greed, or the need for attention spills over to posts that are emphatic and non factual, such as, News today ...4pm or we WILL break .9 today the quality of the board and all the good DD that can be found here gets watered down. As hopeful as most of us are (hopefully I am speaking for most) we do not need non factual and misleading posts here. 10 minutes to go eastern standard.
Big Blue
You stated: It is breaking .009 today.
When you post this type of emphatic and very likely wrong information you are just as bad as the people that write big news coming out today that never does.
Big Blue
Its hard to say. Concerning the building, there was an article (I think it was Sar. Her.) where Tony said that they were bursting at the seems in there old building. Concerning the new employees / building, with the three new distributors (ReliaGene, Lynn Peavey,& ORCH) all signing in the last year (and about 2days) and pushing DNAP’s product it was likely a sound business decision to train and ramp up for more business.
Big Blue
Dorsey, I am hopeful!
Around 6/04, DNAP informed Dutton Associates that they expected Statinome to go into clinical trials late 04 or early 05. I have not seen anything that would suggest that these trials have started. I expect that with some information from the FDA on these types of tests the product could be out within 2 years….. IMHO…..I would love to see Statinome out first over Ovanome. I bel. the current worldwide number one drug is lipitor. This does not directly mean that Statinome would be a cash windfall but I do think that there is a bigger market for Statinome over Ovanome...again this IMHO. The only thing that makes me balk a bit concerning if and when Statinome would/will come out is the last quarterly 10QSB/A. I could not find any mention of Statinome. They mentioned Ovanome several times but not Statinome. However, in the annual report the following was stated about Statinome:
The primary objective of our near term research and development efforts in pharmacogenomics will be to expand our library of predictive drug response tests to include multiple therapeutic areas including commonly used FDA approved drug
therapies. We currently have two pharmacogenomic tests in development, Ovanome TM and Statinome TM . In addition, it is our goal to continue to expand, improve and broaden our current products, ANCESTRYbyDNA TM and DNAWitness TM through
research and development. Although our products are diverse and address different market areas and needs, the base technology is the same.
And…
STATINS AND ACE INHIBITORS
We are developing a test, Statinome(TM), for the cardiac drug market. Statins are drugs used to treat patients at increased risk of heart disease. Approximately 50% of the U.S. population is at risk of heart disease as a result of high cholesterol and related hormonal and other chemical imbalances. While Statins have demonstrated effectiveness at cholesterol reduction, reportedly decreasing incidence of heart disease by 10.3% from 1990 to 1994, adverse
reactions from statins can include liver damage, kidney failure and a form of advanced muscular degeneration. Approximately 2-5% of patients must discontinue
statin use due to these adverse side effects. If accepted for commercial use, we believe Statinome TM will reduce substantially, the risks associated with adverse response.
Our current study includes two adverse side effects associated with statins, liver and adverse muscular response. These two side effects comprise most of the side effects associated with statins. We have identified numerous markers
associated with these potentially life-threatening responses. We have performed initial research in conjunction with a group of physicians to study and classify….
Big Blue
Medical Data Compound Controversy
http://www.thestreet.com/_yahoo/stocks/robertsteyer/10208629.html?cm_ven=YAHOO&cm_cat=FREE&c...
(This is just a portion of the article) Big Blue.
By Robert Steyer
TheStreet.com Staff Reporter
2/15/2005 6:46 AM EST
Click here for more stories by Robert Steyer
This week's Food and Drug Administration advisory committee hearings on Cox-2 arthritis drugs will feature detailed, dense depictions of data that look like a statistical version of the old quiz show Who Do You Trust?
The material filed with the FDA -- as well as research published recently in medical journals and presented at scientific conferences -- is demonstrating that different people can look at the same data and come to wildly varying conclusions.
FDA to Create Independent Safety Board
Tuesday February 15, 11:27 am ET
By Lisa Richwine
http://biz.yahoo.com/rb/050215/health_drugs_4.html
WASHINGTON (Reuters) - The U.S. Food and Drug Administration said on Tuesday it was creating an independent drug safety board after the agency's monitoring of drugs already in the marketplace was criticized amid the withdrawal of arthritis drug Vioxx.
The announcement comes on the eve of a three-day FDA meeting called to discuss the safety of painkillers like Merck & Co. Inc.'s (NYSE:MRK - News) Vioxx that have been linked to an increased risk of heart disease and stroke.
Health and Human Services Secretary Michael Leavitt announced the new safety board in a meeting with FDA staff and was later due to give a news conference.
Criticism of how the FDA monitors the after-market safety of drugs has grown in the past year, starting with concerns about suicides in youth who took antidepressants and followed by Merck's September withdrawal of Vioxx.
Questions have also been raised about the safety of Pfizer Inc.'s (NYSE:PFE - News) Celebrex and Bextra, painkillers similar to Vioxx, and about whether they should remain on the market.
The FDA already has an Office of Drug Safety but consumer groups and some lawmakers have said it lacks sufficient independence and resources.
At a congressional hearing in November, a veteran FDA drug safety scientist testified that the FDA was virtually defenseless against another Vioxx.
The new board will include representatives from the FDA and medical oversight experts from other agencies like the Veterans Administration, an administration official said, and will consult with patient and consumer groups.
The Bush administration proposed a 24 percent increase in funding for FDA's Office of Drug Safety in its recent 2006 budget proposal, including 25 additional employees.
An Excerpt From The American President’s State Of The Union
Because one of the main sources of our national unity is our belief in equal justice, we need to make sure Americans of all races and backgrounds have confidence in the system that provides justice. In America we must make doubly sure no person is held to account for a crime he or she did not commit -- so we are dramatically expanding the use of DNA evidence to prevent wrongful conviction.
Big Blue
Race learned of dead baby
By MEREDITH MANDELL
SUN STAFF WRITER
January 08. 2005 6:01AM
DNA test results have identified the race of "Baby Jane," the female infant whose decomposed body was found floating in an Alachua pond more than a year ago, according to an announcement made Friday by the Alachua County Sheriff's Office.
The new information dramatically reduced a field of 50 possible identities of the baby to eight, said Lt. Jim Troiano, a spokesman for the Sheriff's Office. Detectives had conducted hundreds of interviews to narrow the field of children born several months before the child's death, Troiano said.
"This is a tremendous breakthrough," Troiano said. "We're hoping someone can bring a name forward and bring some closure to Baby Jane."
The results provide further clues to the identity of the infant who was found in August 2003 floating face down in a pond at a former catfish farm near NW 102nd Place off State Road 121.
Autopsy results indicated the baby was about 22 inches tall, two weeks to five months old and had dark hair.
But the autopsy could not determine the cause of death or the child's race.
The Sheriff's Office paid $1,250 to DNAPrint Genomics Inc., a forensics lab in Sarasota, to conduct genetic ancestry tests on a bone sample from the infant's remains.
The results showed that there was a "very high probability" that the child was of sub-Saharan African ancestry and a "high probability" that the parents and or grandparents were of Caribbean descent, Troiano said.
The tests are part of the DNAWitness program, a new patented test offered since 2003. Scientists compared the baby's genetic strains with 176 genetic markers endemic to different ancestries - such as European or sub-Saharan African genetic strains.
"What's exciting about this test is at some point law enforcement agencies are going to realize if you use this in the first week of the investigation, you can eliminate large numbers of people by knowing what there ancestry profile is," said Zack Gaskin, a forensic scientist for DNAPrint Genomics Inc.
Since the test's inception, Gaskin said the lab has conducted just under 60 ancestry tests.
The FBI and Scotland Yard have used the test program and test results have notably helped narrow suspects in the case of convicted Louisiana serial killer Derek Todd Lee, Gaskin said.
Meredith Mandell can be reached at (352) 338-3109 or mandelm@gvillesun.com.
Biofrontera aims at own drug sales in the field of dermatology, which it expects to start in 2007
Drug Pipeline Compound
BF-Derm1 Clinical Phase II for antihistamine-refractory urticaria
Aminolevulinic acid (ALA) Clinical Phase II for basal cell carcinoma and actinic keratosis
5-HT2B- Antagonist Preclinical development for migraine prophylaxis
Sphingomyelinase Inhibitors Lead compounds
Cysteine Protease Inhibitors Lead optimization
Kinase Inhibitor Lead finding
PAR4 Antagonist Lead finding
PAR2 Antagonist Lead finding
Biofrontera is uniquely positioned among its peers by a combination of natural compound screening, isolation, and chemical derivatization with molecular, cellular and whole animal pharmacology.
Patents
Broad portfolio of patents covering technology, animal models, and novel compounds
Customers
and Partners Advalytix AG, Bayer Cropscience AG, Evotec OAI AG, Janssen Pharmaceutica NV (J&J-Group), Kiadis BV, Merck KGaA, Schering AG, Schwarz Biosciences GmbH, Universities and other research institutions
Executive
Board Prof. Hermann Lübbert, PhD, CEO
Stefan Weber, CFO
Supervisory
Board Prof. Axel Kleemann, PhD (Chairman), Timo Hercegfi (Vice Chairman), Richard Gabriel, Hector J. Gomez, MD, PhD, Ulrich Granzer, MD and Prof. Bernd Wetzel, PhD
Finance Start-up financing of € 10.9 mln in February 1998 (including 2 mln € VC-funds)
In May 2000 Series A round of € 11.6 mln (including 8.7 mln € VC-funds), led by 3i Group
Acquisition of bioleads' assets in 2003, supported and financed by a € 11.6 mln 1st closing of a Series B financing round led by Heidelberg Innovation (including 7.6 mln € VC-funds)
In September 2004 strategic investment by DNAPrint of 20 mln €. Heidelberg Innovation, 3i, TMK and Prof. Dr. Riesner completed the investment to 21.2 mln €.
Investors
DNAPrint genomics Inc., Heidelberg Innovation, 3i, LeVenture, TMK, Prof. Dr. Detlef Riesner, Pricap, TRE, Richard Gabriel, Monica Tamborini, tbg
Team and Premises Staff of 55 on 2000 m2 of fully equipped laboratory space each in Heidelberg and Leverkusen
Law Enforcement Independently Validate DNAPrint's Forensics Tests
Posted on: 01/22/2003
SARASOTA, Fla. -- DNAPrint genomics, Inc., the world leader in the measurement of population structure for disease genetics, personalized medicine and forensics profiling, announced today that two of its forensics tests have successfully passed second-party blind validations. The results constitute an important step towards gaining acceptance for the new technology in the forensics community.
Two major forensic science organizations and one major metropolitan police department, that will remain unidentified, have independently validated the performance of Ancestry 2.0, the world's first genetic test for determining individual ancestry admixture proportions. Each submitted DNA samples of concealed identity and DNAPrint returned the results for evaluation. For each sample, the majority ancestry determined matched the self-reported race and when detected, the admixture was consistent with what was known from the family history. Another major molecular forensics company has independently and similarly validated DNAPrint's RETINOME test, which is the world's first test for the determination of iris color from DNA. DNAPrint expects to publish details on both methods in the near future.
"Our results to date from more than 1,800 blind trials have shown that biogeographical ancestry knows few geopolitical or cultural boundaries and that through admixture, we are more connected to one another than had previously been believed," said Dr. Tony Frudakis, PhD, CEO of DNAPrint genomics. "The results obtained to date support our vision that the accurate measurement of individual ancestry admixture proportions and elements of population structure correlated with human pigmentation will ultimately contribute toward the construction of physical profiles from crime scene DNA."
AncestrybyDNA is a revolutionary genetics test for determining ancestral admixture analysis within individuals. Specifically, the test measures the proportionality of IndoEuropean, sub-Saharan African, East Asian-Pacific Islander and Native American ancestry, and in so doing provides an estimate of identity or affiliation with each of the world's major continental populations. Ancestry 2.0 is the forensics brand of AncestrybyDNA. DNAPrint's Ancestry technology was originally developed as the cornerstone of the Companies ADMIXMAP platform for using admixture to map complex, common disease and drug response genes. In addition to the forensics labs discussed in this press release, the test has been independently validated by US News and World Report, Popular Science Magazine, Miami's WPLG Channel 10, Tampa's FOX Channel 13 news, Germany's ZDF news Channel, Discovery Europe, and the Australian Broadcasting Corporation. The test has been featured in articles by the New York Times, World Business Reports Financial Times, UPI and the Sarasota-Bradenton Herald and will be the focus of an upcoming edition of CBS Eye on America with Wyatt Andrews.
DNAPrint genomics Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. Using proprietary human genome research methods, the Company develops chemopredictive tests for matching patients with drugs based on their genetic constitution, discovers disease genes for the development of new drugs and develops new forensic genomics and recreational genomics testing products.
News on Friday eh?
Okay we'll see but keep in mind that CRAP posts like this one (if there is no new news on Friday) are just as bad as the posts that bash for no reason.
Big Blue
Law Enforcement Independently Validate DNAPrint's Forensics Tests
Posted on: 01/22/2003
SARASOTA, Fla. -- DNAPrint genomics, Inc., the world leader in the measurement of population structure for disease genetics, personalized medicine and forensics profiling, announced today that two of its forensics tests have successfully passed second-party blind validations. The results constitute an important step towards gaining acceptance for the new technology in the forensics community.
Two major forensic science organizations and one major metropolitan police department, that will remain unidentified, have independently validated the performance of Ancestry 2.0, the world's first genetic test for determining individual ancestry admixture proportions. Each submitted DNA samples of concealed identity and DNAPrint returned the results for evaluation. For each sample, the majority ancestry determined matched the self-reported race and when detected, the admixture was consistent with what was known from the family history. Another major molecular forensics company has independently and similarly validated DNAPrint's RETINOME test, which is the world's first test for the determination of iris color from DNA. DNAPrint expects to publish details on both methods in the near future.
"Our results to date from more than 1,800 blind trials have shown that biogeographical ancestry knows few geopolitical or cultural boundaries and that through admixture, we are more connected to one another than had previously been believed," said Dr. Tony Frudakis, PhD, CEO of DNAPrint genomics. "The results obtained to date support our vision that the accurate measurement of individual ancestry admixture proportions and elements of population structure correlated with human pigmentation will ultimately contribute toward the construction of physical profiles from crime scene DNA."
AncestrybyDNA is a revolutionary genetics test for determining ancestral admixture analysis within individuals. Specifically, the test measures the proportionality of IndoEuropean, sub-Saharan African, East Asian-Pacific Islander and Native American ancestry, and in so doing provides an estimate of identity or affiliation with each of the world's major continental populations. Ancestry 2.0 is the forensics brand of AncestrybyDNA. DNAPrint's Ancestry technology was originally developed as the cornerstone of the Companies ADMIXMAP platform for using admixture to map complex, common disease and drug response genes. In addition to the forensics labs discussed in this press release, the test has been independently validated by US News and World Report, Popular Science Magazine, Miami's WPLG Channel 10, Tampa's FOX Channel 13 news, Germany's ZDF news Channel, Discovery Europe, and the Australian Broadcasting Corporation. The test has been featured in articles by the New York Times, World Business Reports Financial Times, UPI and the Sarasota-Bradenton Herald and will be the focus of an upcoming edition of CBS Eye on America with Wyatt Andrews.
DNAPrint genomics Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. Using proprietary human genome research methods, the Company develops chemopredictive tests for matching patients with drugs based on their genetic constitution, discovers disease genes for the development of new drugs and develops new forensic genomics and recreational genomics testing products.
Source: DNAPrint genomics, Inc.
Ifida,
That post says nothing about holding off on R-HA....but I liked reading it again.
Big Blue
Thanks again Doug.
Big Blue
DougS
Thank you for the info!
Did you see this info in an article? Do you have a link?
Thanks again.
Big Blue.
RETINOME-HA....
....is one of the keys to the DNA fuzzy photograph . It was suppose to be done around the same time that Retinome came out.
Does anyone here know what's going on with this product? For the love of all that's good, Anybody?
Big, Blue
Below is a link regarding Retinome:
http://www.forensicfocusmag.com/hotnews/3bh2573837.html
DNAPrint Announces Forensic Eye Color Results at Amsterdam Forensic Meeting; World's First Genomics-Derived Test For Forensics Investigation With Predictive Capabilities
Posted on: 11/25/2003
SARASOTA, Fla. -- DNAPrint genomics, Inc. announced progress Nov. 20, 2003 in developing anthropomorphic genomics testing products to an audience of approximately 500 forensic scientists and detectives at the "DNA ... sporen naar de toekomst II" conference sponsored by the Netherlands Forensic Institute.
In 2002, DNAPrint filed a patent application on numerous genetic sequences associated with and predictive for human iris color. The sequences discovered by DNAPrint scientists are known as "markers," and to demonstrate that the predictive value for the markers extends to other sets of samples, DNAPrint initiated an internal validation trial using newly collected samples from across the United States. It was reported in this conference that:
1) Most of the markers originally identified have been validated as generally associated with iris color.
2) The associations for a majority of the markers in the new set of samples are at least as strong as those observed in the set of samples previously studied, and
3) DNAPrint has completed the screening of an additional 11,000 polymorphisms across the human genome to identify and validate a number of additional human iris color markers.
From its screen of a total of 13,000 polymorphisms in over 1,200 samples, 40 markers from a number of human chromosomes (notably chromosomes 1 and 15) have been identified as associated with iris color in individuals of majority European BioGeographical Ancestry (BGA). Iris color classification accuracy in the validation set, called "within-model" accuracy, was calculated at 97 percent considering a two-group classification scheme (dark and light). Dr. Frudakis, on behalf of DNAPrint, reported that he is already engaged in the next step of the validation process -- to blindly challenge the classifier as the DNAPrint scientists did with the ANCESTRYbyDNA 2.0 test last year. Pending the outcome of this trial, a classifier incorporating these markers, DNAPrint will be the first to introduce eye color determination (either Blue or Brown or some other color) from a crime scene sample and the world's second commercially introduced anthropometric test for the construction of physical profiles from crime scene DNA.
During the presentation, DNAPrint also announced that some of the early work on human iris color has been accepted for publication in the peer-reviewed journal "Genetics." The paper "Sequences Associated with Human Iris Pigmentation" will appear in the upcoming December issue, and represents the first systematic post-genome era study of human iris color to have yet been published. DNAPrint was one of the first to identify more markers and prior to this work, few markers for human iris color were known, and it had not been possible to predict iris color from DNA (nor any other anthropometric trait) with good sensitivity and/or specificity. Several of the markers described in this paper are necessary (but not sufficient) to infer iris color from DNA; the paper represents about 1/5th of the research conducted by DNAPrint in this area.
Also discussed at the conference was the progress implementing the world's first genome based anthropometric test -- DNAWitness 2.0, which allows for the quantitative measurement of BioGeographical Ancestry (BGA), or the heritable component of race. DNAPrint introduced a novel database system and algorithms to allow investigators to make accurate and objective inferences about certain elements of physical appearance from a DNAWitness 2.0 BioGeographical Ancestry admixture profile. The system allows the customer to query the database with a BGA profile and visualize historically typed samples and to computationally infer values for certain anthropometric traits. For certain traits, and in certain BGA groups, BGA admixture can be used to make accurate predictions of trait value and the system was described as integral for allowing an empirical construction of partial physical profiles from crime scene DNA.
"We are moving closer to the day when a fuzzy photograph of the criminal will be available to the detectives based on the DNA left at the crime scene," said Dr. Tony Frudakis, CSO of DNAPrint genomics, Inc. "It is imperative that we introduce these new advances to the forensics and detectives community as soon as possible, once they have been validated. We continue to work with law enforcement officers, forensic scientists, medical examiners and other scientists to broaden and strengthen our product's performance."
"DNAPrint is on the leading edge of this new technology and it will continue to focus its resources and efforts on introducing new products and services that will increase our market awareness," said Richard Gabriel, CEO and president of DNAPrint. "The value of this product to an investigator searching for a killer, rapist or child molester can not be quantified but we can measure our performance as a part of the investigative team and as a tool used by investigators to help bring the offender to justice. I should emphasize that without the integration of this new tool into the investigative process and the hard work and dedication of the investigators, forensic scientists, medical examiners and witnesses, this test would have remained a laboratory curiosity but the facts are clear ... by helping the task force in Louisiana ... who contacted us in the quickest possible time after we announced the product ... until they caught the suspect, was less than 12 weeks. Furthermore, in California by working with the task force, we were able to help them focus on a narrower list of suspects which was gathered by their detectives and scientists using hard nosed, grueling investigative work in the field and in the crime lab, to result in another arrest of a suspect within 6 weeks." He said, "The DNAWitness 2.0 product can be used by investigators, forensic scientist and medical examiners as another tool in the investigative process. This product will help identify the appropriate group of suspects, based on scientific DNA evidence left at the crime scene and not based on other less-acceptable forms of suspect identification."
DNAPrint genomics Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. The DNAWitness analysis is a direct result of focused research by the DNAP research and development team.
In addition, using proprietary human genome research methods, the company develops pharma-predictive tests for matching patients with drugs based on their genetic constitution, discovers disease genes for the development of new drugs and develops new forensic genomics and recreational genomics testing products.
Source: DNAPrint genomics, Inc.
RETINOME-HA
Does anyone here know what's going on with this product?
Anyone? Anyone?
Big, what's a brother gotta do to get some love, Blue
Faces In The News
Senator Dodd: Proposes Sweeping Drug Safety Reform
Matthew Herper, 01.21.05, 2:02 PM ET
NEW YORK - Doers and doings in business, entertainment and technology:
Senator Christopher J. Dodd
http://www.forbes.com/facesinthenews/2005/01/21/0121autofacescan03.html?partner=yahoo&referrer=
Connecticut Senator Christopher J. Dodd, a Democrat, is proposing a sweeping set of drug reforms that would give the Food and Drug Administration the muscle to force pharmaceutical companies to study drug safety after the medicines are approved. If drug companies ran afoul of the FDA, they might be fined as much as $10,000 per day. The bill, called the Patient Protection Act of 2005, would have no effect on the approval process for drugs. Instead, it gives the FDA more power to regulate medicines after they are approved, filling what he said were "gaping holes" in the agency's ability to enforce its decisions. "'FDA-approved' is just about as good a brand as we have," said Dodd. The point of the bill is to make that brand stronger. He said the bill would "put some real teeth into the FDA."
RETINOME-HA
Does anyone here know what's going on with this product?
Police hail swift DNA technology
Sunday, December 12, 2004
By Jonathan D. Silver, Pittsburgh Post-Gazette
http://www.post-gazette.com/pg/04347/425686.stm
In the mid-1980s, Paul McComb was a Pittsburgh police detective investigating a sexual assault on a woman.
After some footwork, McComb and his partner made an arrest. McComb knew he had the right person. But to make absolutely sure, authorities ran the suspect's blood through a relatively new-fangled DNA test that had recently debuted in England.
"We got a positive match," recalled McComb, who today is a sergeant running the department's crime unit. "Getting a confession sometimes isn't enough. With the DNA evidence, it was a solid, solid case, and he's still in jail."
Since that time, DNA technology -- and its use in crime fighting -- has undergone an amazing transformation. Samples of a human being's genetic material that were once considered too small, too old or too contaminated to be used in a case are now considered viable. Large DNA databases of criminals have been compiled and are used regularly by law enforcement. And DNA is being mined for ever more detailed information in a shorter amount of time.
"I never thought we would be able to get samples from a baseball hat, or the swabbing of eyeglasses, 15 years ago when I started because we needed a quarter-sized drop of blood in the early 1990s. Now I don't even need to see a stain," said Beth Ann Marne, supervisor of the DNA laboratory for the Pennsylvania State Police.
Experts who track developments in DNA technology and law enforcement envision policing only getting better and faster because of scientific advances.
Robotics and automation are trimming the time it takes to process DNA samples. A local software company, Cybergenetics in Oakland, has done the same for analyzing and interpreting the results. A group in Florida is able to deduce ethnicity and eye color from DNA samples, which could help police narrow down a list of suspects.
The world of tomorrow might even contain portable devices to scan DNA right at crime scenes. Someday, if the arguments of civil libertarians can be outmaneuvered, there might be a national DNA database formed from samples taken at birth.
Britain at the forefront
Twenty years ago, British scientist Sir Alec Jeffreys made a discovery that changed the course of DNA technology. Jeffreys proved that people have unique genetic fingerprints. His technique was quickly applied to police work. DNA fingerprinting ruled out a suspect in a double rape and homicide in England and then helped convict the culprit.
Today, England still leads the way in using DNA for fighting crime through the country's Forensic Science Service. The agency takes credit for establishing the world's first national criminal intelligence DNA database.
Mark Perlin, chief executive officer of Cybergenetics, is familiar with how British forensic work operates. His company's software for analyzing and interpreting the results of testing DNA from property crime scenes is used by the Forensic Science Service.
Perlin said the British emphasize DNA technology for investigation rather than trial, as is the focus in the United States. Instead of using DNA primarily in the courtroom, the British use it as a matter of course during investigations of such offenses as burglaries.
In Britain, rapists and murderers have been convicted because of matches of crime-scene evidence with DNA taken after the suspects had been charged with other minor crimes, including disorderly conduct and shoplifting.
McComb said his 12-member crime unit did not collect DNA from every crime scene. It would not be feasible, especially considering the backlog in cases at Allegheny County's crime lab.
"Will we spend three hours there with a light source looking for saliva, urine, hairs etc.? No. It's not practical," McComb said.
Officers in Britain can take a mouth swab for DNA testing from anyone detained and arrested. The DNA is sent for processing and comparison with known offenders and crime-scene evidence. Then reports on the matching profiles are sent back to the police.
In this country, police need search warrants to obtain DNA samples from people. In order to obtain a warrant, they need probable cause that someone has committed a crime. Judges must sign off on the warrant.
All the crime-scene DNA in the world won't help police if there isn't an offender to whom it can be matched.
Expanding DNA databases
Last month, Gov. Ed Rendell signed into law a bill that requires all convicted felons to submit DNA samples to state police, thereby expanding Pennsylvania's database.
All 50 states maintain DNA databases, and the FBI oversees a national database. States have different requirements for who must submit DNA samples, but University of Wisconsin-Madison law professor Michael E. Smith said no matter where you look, the trend is for including more information, not less.
However, Smith said, DNA databases are skewing toward including more black men than white men, leading to concerns about racial disparity.
"The databases are building and they're getting bigger all the time and more comprehensive and more racially distorted," Smith said. "If we want to meet the maximum value for crime control and public safety purposes, we really want to have a near-universal database. We do want to be able to identify people if they leave DNA at a crime scene."
In the United States, California has what the American Civil Liberties Union calls the "most draconian DNA database system in the country" after the recent approval by voters of Proposition 69, which will require in 2009 that people arrested for felonies, but not convicted, submit a DNA sample. The ACLU has filed a class-action suit saying the law is unconstitutional.
A 'fuzzy' photo
In the absence of matching crime-scene DNA with a known felon, a Florida-based company is doing the next best thing. DNAPrint Genomics is working to create a picture for investigators of what a suspect might look like.
It's hardly a perfect science. But the company believes it can provide police with a "fuzzy photograph" of a culprit based on a determination of likely ethnicity.
From DNA, the company can tell what percentage of a person's genetic makeup is likely to be black, white, Asian and American Indian. With those percentages, DNAPrint Genomics can consult a book of "mug shots" submitted by volunteers who have had their own DNA screened.
Depending on what the DNA at a crime scene reveals about a suspect's genetic makeup, the company can provide a range of pictures of other people with similar genetic profiles, giving investigators a rough idea of the person's general appearance.
"It's our feeling that really what we're doing is placing an eyewitness at the crime scene just by looking at the DNA," said Zach Gaskin, the company's technical coordinator of forensics. "If a guy is 95 percent Sub-Saharan African, you know you're not looking for someone who is Caucasian, East Asian or Hispanic."
In the future, DNAPrint Genomics might be able to tell far more about a suspect than ethnicity and eye color. Figuring out how genes dictate, say, the shape of someone's nose might help immensely to creating what Gaskin called a "genetic sketch."
"In theory, yes, I think it's possible that we'll be able to produce a general sketch. And what we're doing now is producing a fuzzy photo, a driver's license photo with the picture smudged and no information on it."
http://www.heraldtribune.com/apps/pbcs.dll/article?AID=/20030604/NEWS/306040526/1007&cachetime=5
DNAPrint plays role in capture
A published report says investigators in the Louisiana serial killings used the Sarasota firm's genetics test.
STAFF AND WIRE REPORT
SARASOTA -- A genetics test owned by DNAPrint Genomics Inc. helped lead investigators to a suspect in a string of Louisiana murders.
Authorities arrested Derrick T. Lee in Atlanta last week in connection with the killings of at least five southern Louisiana women since September 2001, as well as two earlier slayings.
Citing a confidentiality agreement with Louisiana authorities, Tony Frudakis, DNA- Print's chief science officer, said he couldn't confirm that the company's test was used in the case.
But Mark Shriver, an assistant professor of anthropology and genetics at Pennsylvania State University, told The New York Times in a story published Tuesday that investigators used the test. Shriver, who collaborated on the development of DNAPrint's ANCESTRYbyDNA 2.0, said its findings caused them to shift their focus away from white suspects. An analysis of tissue from one of the crime scenes determined that the killer was probably black.
Shriver, who could not be reached Tuesday, told the Times that investigators had been searching for a white man based on profiling information suggesting that most serial killers are white.
The Times reported that one of the DNA samples sent by police to the Sarasota research company was linked to the suspect. Analysis showed it came from a person who has 85 percent African ancestry and 15 percent American Indian.
Lee, 34, is black. Shriver told the Times he didn't know whether Lee had any Indian ancestors.
On Tuesday, the Louisiana attorney general's office referred calls for comment to a serial killer task force in Baton Rouge, which did not return calls.
The ANCESTRY test distinguishes within a few percentage points to what extent a person is of European, American Indian, African, Asian or Pacific Islander heritage.
Frudakis said the test now is being used by about 10 law enforcement agencies, primarily in the Southeast. The company also markets it to genealogy enthusiasts as the first "recreational" testing of its kind.
DNA evidence has come into widespread use to identify individuals, but the identifying pieces of DNA are not part of the genes and have no influence on a person's physical makeup. Experts have long recognized that as knowledge of the human genome advances, other information could be extracted from DNA samples, including physical traits like race.
Human DNA is 99.9 percent identical. The remaining 0.1 percent distinguishes one person from another.
The Louisiana serial killer case appears to be the first use of DNA to extract details of a criminal suspect's appearance.
Barry C. Scheck, director of the Innocence Project at the Benjamin Cardozo School of Law, which uses DNA evidence to reverse false convictions, said he was unfamiliar with DNAPrint's test but that he had used DNA markers from a single gene to argue that a person was more likely to be one race than another.
Dr. Barry Duceman, director of biological sciences at the New York State Police forensic investigation center, said a suspect's sex was often determined from DNA. As far as cases where other physical characteristics were concerned, he said, "This is the first that I'm aware of."
"My prediction is that the test will become more utilized," said Dr. Mark Batzer, a population geneticist at Louisiana State University, where the killer's last victim, Carrie Lynn Yoder of Tampa, was a graduate student. Batzer said he was aware of the racial profiling test and had encouraged its use when his advice was sought by a Louisiana police laboratory.
On Tuesday, DNAPrint's Frudakis was interviewed by ABC's "Primetime Thursday." The segment is scheduled to air June 12. In March, CBS twice aired a segment about the company's test on "Eye on America with Dan Rather."
Margaret Ann Miille contributed to this report, which contains information from The Associated Press and The New York Times News Service.
Last modified: June 04. 2003 12:00AM
The US Patent Office unfortunately does not list any Patents for DNAP.
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2Fsearch-adv...
Long & Buying